AUPH

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +47.37%. A quarter ago, it was expected that this biotechnology company would post earnings of $0.18 per share when it actually produced earnings of $0.25, delivering a surprise of +38.89%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Aurinia, which belongs to the Zacks Medical - Drugs industry, posted revenues of $83.22 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.1%. This compares to year-ago revenues of $70.01 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Aurinia shares have lost about 4.8% since the beginning of the year versus the S&P 500's gain of 12.8%. While Aurinia has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Aurinia was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.20 on $84.85 million in revenues for the coming quarter and $0.85 on $332.6 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, MARKER THERAPEUTICS, INC. (MRKR), is yet to report results for the quarter ended June 2026. This company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of +13.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. MARKER THERAPEUTICS, INC.'s revenues are expected to be $0.6 million, down 30.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Aurinia Pharmaceuticals Inc (AUPH) : Free Stock Analysis Report MARKER THERAPEUTICS, INC. (MRKR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

ROCKVILLE, Md. & EDMONTON, Alberta, August 06, 2026--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three and six months ended June 30, 2026, total revenue was $83.2 million and $160.9 million, up 19% and 21%, respectively, from $70.0 million and $132.5 million, respectively, in the same periods of 2025. Net Income: For the three and six months ended June 30, 2026, net income was $37.4 million and $71.8 million, up 74% and 60%, respectively, from $21.5 million and $44.9 million, respectively, in the same periods of 2025. Diluted Earnings per Share: For the three and six months ended June 30, 2026, diluted earnings per share was $0.28 and $0.53, up 75% and 66%, respectively, from $0.16 and $0.32 in the same periods of 2025. Cash Flows from Operating Activities: For the three and six months ended June 30, 2026, cash flows from operating activities were $52.5 million and $85.1 million, up 19% and 87%, respectively, from $44.2 million and $45.5 million in the same periods of 2025. Cash Position As of June 30, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $443.1 million, compared to $398.0 million at December 31, 2025. For the six months ended June 30, 2026, cash outflows from financing activities were $48.9 million, which included the repurchase of 5.0 million of the Company’s common shares for $74.9 million, partially offset by proceeds from issuance of common shares for equity awards, net of tax withholding payments, of $32.7 million. 2026 Total Revenue and Net Product Sales Guidance Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and 2026 net product sales of $305 million to $315 million, up 12% to 16% compared to 2025. Recent Development Progress LUPKYNIS Aurinia has recently initiated PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis. Belimumab is a B cell-activating factor (BAFF) inhibitor indicated for the treatment of both systemic lupus erythematosus (SLE) and lupus nephritis. Obinutuzumab is a CD20-directed cytolytic antibody indicated for the treatment of lupus nephritis. Anifrolumab is a type 1 interferon receptor antagonist indicated for the treatment of SLE. PRESERVE will investigate whether the multi-target approach of combining LUPKYNIS with these biologic agents improves outcomes in patients with lupus nephritis. Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study’s primary endpoint is the proportion of patients achieving complete renal response (CRR) at 6 months. Aritinercept Aritinercept is a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Aurinia has now initiated clinical development of aritinercept in four potential indications. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Forward-Looking Statements This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: LUPKYNIS net product sales, the timing of clinical study results and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260806708746/en/ Contacts Investor Inquiries [email protected]

Even though Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) posted strong earnings recently, the stock hasn't reacted in a large way. We think that investors might be worried about the foundations the earnings are built on. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Many investors haven't heard of the accrual ratio from cashflow, but it is actually a useful measure of how well a company's profit is backed up by free cash flow (FCF) during a given period. The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. The ratio shows us how much a company's profit exceeds its FCF. As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". Over the twelve months to March 2026, Aurinia Pharmaceuticals recorded an accrual ratio of 1.16. Ergo, its free cash flow is significantly weaker than its profit. As a general rule, that bodes poorly for future profitability. To wit, it produced free cash flow of US$167m during the period, falling well short of its reported profit of US$298.2m. At this point we should mention that Aurinia Pharmaceuticals did manage to increase its free cash flow in the last twelve months Importantly, we note an unusual tax situation, which we discuss below, has impacted the accruals ratio. This would partially explain why the accrual ratio was so poor. One positive for Aurinia Pharmaceuticals shareholders is that it's accrual ratio was significantly better last year, providing reason to believe that it may return to stronger cash conversion in the future. As a result, some shareholders may be looking for stronger cash conversion in the current year. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Moving on from the accrual ratio, we note that Aurinia Pharmaceuticals profited from a tax benefit which contributed US$164m to profit. It's always a bit noteworthy when a company is paid by the tax man, rather than paying the tax man. Of course, prima facie it's great to receive a tax benefit. However, our data indicates that tax benefits can temporarily boost statutory profit in the year it is booked, but subsequently profit may fall back. Assuming the tax benefit is not repeated every year, we could see its profitability drop noticeably, all else being equal. This year, Aurinia Pharmaceuticals couldn't match its profit with cashflow. If the tax benefit is not repeated, then profit would drop next year, all else being equal. For all the reasons mentioned above, we think that, at a glance, Aurinia Pharmaceuticals' statutory profits could be considered to be low quality, because they are likely to give investors an overly positive impression of the company. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. Case in point: We've spotted 2 warning signs for Aurinia Pharmaceuticals you should be aware of. In this article we've looked at a number of factors that can impair the utility of profit numbers, and we've come away cautious. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

ROCKVILLE, Maryland & EDMONTON, Alberta, May 07, 2026--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months ended March 31, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three months ended March 31, 2026, total revenue was $77.7 million, up 24% from $62.5 million in the same period of 2025. Net Product Sales: For the three months ended March 31, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $73.6 million, up 23% from $60.0 million in the same period of 2025. License, Collaboration and Royalty Revenue: For the three months ended March 31, 2026, license, collaboration and royalty revenue from Aurinia’s collaboration partner, Otsuka, was $4.1 million, up 64% from $2.5 million in the same period of 2025. Net Income: For the three months ended March 31, 2026, net income was $34.4 million, up 48% from $23.3 million in the same period of 2025. Diluted Earnings per Share: For the three months ended March 31, 2026, diluted earnings per share was $0.25, up 56% from $0.16 in the same period of 2025. Cash Flows from Operating Activities: For the three months ended March 31, 2026, cash flows from operating activities were $32.6 million, up 2408% from $1.3 million in the same period of 2025. Cash Position As of March 31, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $378.8 million, compared to $398.0 million at December 31, 2025. For the three months ended March 31, 2026, cash outflows from financing activities were $53.7 million, which included the repurchase of 2.5 million of the Company’s common shares for $36.2 million and tax withholding payments related to net settlements of equity awards of $14.6 million. 2026 Total Revenue and Net Product Sales Guidance Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and 2026 net product sales of $305 million to $315 million, up 12% to 16% compared to 2025. "Aurinia remains steadfast in its mission to become a leading company that benefits patients suffering from autoimmune diseases," stated Kevin Tang, Chief Executive Officer. "LUPKYNIS is emerging as a standard-of-care treatment for lupus nephritis, and aritinercept, now in clinical development for three potential indications, has therapeutic potential across a wide range of autoimmune disorders." About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Forward-Looking Statements This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: LUPKYNIS net product sales, the timing of clinical study results and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260507497614/en/ Contacts General Investor Inquiries [email protected]

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +38.89%. A quarter ago, it was expected that this biotechnology company would post earnings of $0.21 per share when it actually produced earnings of $0.26, delivering a surprise of +23.81%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Aurinia, which belongs to the Zacks Medical - Drugs industry, posted revenues of $77.71 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.39%. This compares to year-ago revenues of $62.47 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Aurinia shares have added about 1.9% since the beginning of the year versus the S&P 500's gain of 7.6%. While Aurinia has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Aurinia was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.19 on $82.5 million in revenues for the coming quarter and $0.81 on $329.9 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Journey Medical Corporation (DERM), another stock in the same industry, has yet to report results for the quarter ended March 2026. This company is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of +61.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Journey Medical Corporation's revenues are expected to be $15.08 million, up 14.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Aurinia Pharmaceuticals Inc (AUPH) : Free Stock Analysis Report Journey Medical Corporation (DERM) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news from United Therapeutics and Biogen, as well as updates from Eli Lilly, Novo Nordisk and Aurinia Pharmaceuticals that you may have missed. Shares of United Therapeutics were up nearly 15% Monday morning on data from a late-stage clinical trial that assessed the company’s already-marketed drug Tyvaso in patients with a rare lung condition known as idiopathic pulmonary fibrosis. Another, similar trial had previously hit its main goal. According to United, the newer results — from a study titled TETON-1 — were even better. After a year of treatment, patients given Tyvaso showed an absolute change in “forced vital capacity” of 130.1 mL. FVC is a key test for potential IPF treatments, as it measures lung health by quantifying how much air a patient can forcefully exhale after taking a deep breath. Tyvaso is currently used for a lung-related illness called pulmonary arterial hypertension. The data from TETON-1 should “favorably shift the Tyvaso narrative away from the nuances” of the competitive PAH market and towards the “more ‘green field’ blockbuster opportunity” of IPF, according to Leerink Partners analyst Roanna Ruiz. Biogen on Monday said the Food and Drug Administration approved a higher-dose version of the company’s spinal muscular atrophy drug Spinraza. The new regimen will be available in the coming weeks, according to Biogen, and allows for an accelerated loading phase. Two 50 milligram doses are administered 14 days apart, followed by 28 milligram maintenance dose injections every four months thereafter. The approval should keep Biogen’s SMA franchise “durable” and serve as a bridge until the company’s next-generation medicine, “salanersen,” comes to market, wrote Jefferies analyst Andrew Tsai in a note to clients. Tsai added that his team expects the Spinraza franchise, which generated roughly $1.5 billion in sales last year, to “remain resilient (or even grow)” despite the SMA market possibly getting more crowded over the next couple years. The FDA has approved Novo Nordisk’s Awiqli as an adjunct treatment to diet and exercise to improve blood sugar control in adults with Type 2 diabetes. The FDA based its decision on data from four studies that enrolled nearly 2,700 patients and tested weekly shots of Awiqli. According to Novo, this is the first once‑weekly basal insulin option approved for adult Type 2 diabetes patients in the U.S., and thereby provides “a new treatment solution that fits different patient routines and preferences.” The Denmark-based drugmaker said it plans to launch Awiqli in its FlexTouch devices in the states in the second half of this year. In other Biogen news, the company’s experimental drug litifilimab succeeded in a mid-stage study of patients with cutaneous lupus erythematosus, an autoimmune condition marked by skin inflammation, scaly rashes and oral sores. According to a Saturday announcement from Biogen, the first part of the “AMETHYST” trial met its main objective, with litifilimab demonstrating an 11.8% higher reduction in disease activity compared to a placebo after 16 weeks of treatment. The results were consistent with what researchers observed in “LILAC,” a separate CLE study. A targeted antibody drug, litifilimab is also being evaluated as a treatment for another kind of lupus known as SLE. Aurinia Pharmaceuticals has agreed to acquire Kezar Life Sciences, a San Francisco-area biotech developing small molecule drugs for cancer and conditions where the immune system mistakenly attacks the body’s own healthy cells. For each share of Kezar’s common stock, Aurinia has agreed to hand investors just shy of $7 in cash, plus one non-transferable contingent value right that floats potential payments if certain goals are hit. The deal, announced Monday, comes after Kezar’s board of directors conducted a strategic review and unanimously determined that Aurinia’s proposal is in the best interests of the biotech and its stockholders. Kezar’s most advanced drug, zetomipzomib, is being evaluated as a possible treatment for autoimmune hepatitis, SLE and a kidney illness caused by SLE. Aurinia’s CEO Kevin Tang previously made a bid as an activist shareholder to acquire Kezar in 2024. Eli Lilly’s Ebglyss kept moderate-to-severe eczema in check for up to four years in a late-stage clinical trial, the company disclosed Friday. The open-label extension study showed 80% of participants who were given a once-monthly maintenance injection of Ebglyss experienced a durable response without the need for topical corticosteroids. Three-quarters of participants achieved “EASI90” — a test that signals near-complete skin clearance — while 78% reported significant itch relief. An antibody drug, Ebglyss works by inhibiting an immune system-regulating protein called IL-13. Sanofi and Regeneron’s Dupixent also targets IL-13 as well as the related protein IL-4. Recommended Reading Ovid partners with Waksal startup to develop drugs for rare brain disorders

In late February 2026, Aurinia Pharmaceuticals reported fourth-quarter 2025 revenue of US$77.11 million and full-year revenue of US$283.06 million, alongside a jump in net income to US$287.2 million and basic earnings per share of US$2.14 from continuing operations. The company also issued 2026 guidance calling for total revenue of US$315 million to US$325 million and net product sales of US$305 million to US$315 million, signaling management’s confidence in ongoing LUPKYNIS momentum and operational execution. We’ll now examine how this combination of very large year-on-year earnings growth and double-digit 2026 revenue guidance affects Aurinia’s investment narrative. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. To own Aurinia, you need to believe LUPKYNIS can support a durable, profitable franchise while the pipeline, led by aritinercept, matures into a second growth pillar. The latest results, with a sharp jump in 2025 earnings and management guiding to US$315–325 million in 2026 revenue, reinforce the near term earnings story but do not remove the core risk of heavy dependence on a single drug and ongoing scrutiny of LUPKYNIS exclusivity. Among recent announcements, the 2026 revenue and net product sales guidance stands out as most relevant. Management’s outlook for 11–15% total revenue growth and 12–16% LUPKYNIS sales growth ties directly into the key catalyst of continuing adoption supported by clinical guidelines, while also highlighting the tension with the main risk factor: how long LUPKYNIS can remain the primary engine before competition, pricing pressure, or pipeline execution start to matter more. Yet beneath the strong 2025 earnings and upbeat 2026 guidance, investors should be aware that... Read the full narrative on Aurinia Pharmaceuticals (it's free!) Aurinia Pharmaceuticals' narrative projects $386.4 million revenue and $141.3 million earnings by 2028. This requires 14.1% yearly revenue growth and a $80.7 million earnings increase from $60.6 million today. Uncover how Aurinia Pharmaceuticals' forecasts yield a $16.67 fair value, a 17% upside to its current price. Some of the most optimistic analysts were already penciling in around US$483 million in revenue and US$255 million in earnings by 2028, so this fresh guidance and the reliance on LUPKYNIS could either support their bullish case or force a rethink, reminding you that reasonable people can read the same numbers very differently and that it is worth comparing several views before you decide what you believe. Explore 6 other fair value estimates on Aurinia Pharmaceuticals - why the stock might be worth 21% less than the current price! Don't just follow the ticker - dig into the data and build a conviction that's truly your own. A great starting point for your Aurinia Pharmaceuticals research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision. Our free Aurinia Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Aurinia Pharmaceuticals' overall financial health at a glance. Our top stock finds are flying under the radar-for now. Get in early: The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AUPH. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

This article first appeared on GuruFocus. Release Date: February 26, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) reported a 29% increase in total revenue for Q4 2025 compared to the same period in 2024. Net product sales of Lukiness grew by 25% year-over-year, indicating strong market demand. The company achieved a significant increase in net income for Q4 2025, up 14,957% from the previous year, primarily due to the release of its valuation allowance on deferred tax assets. Cash flows from operating activities increased by 52% in Q4 2025 compared to Q4 2024, reflecting improved operational efficiency. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has initiated a clinical study of Ari intercept in one autoimmune disease and plans to start another in the first half of 2026, showing progress in their pipeline development. The guidance for 2026 appears conservative despite strong Q4 2025 performance, raising questions about future growth assumptions. The company terminated the phase 3 and open-label studies in the vocal study due to recruitment challenges, indicating potential setbacks in clinical development. There is uncertainty regarding the competitive impact of new entrants like Gazaga in the lupus nephritis market. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) faces challenges in achieving global market penetration similar to the US due to varying pricing and reimbursement landscapes. The company is not providing specific commercial metrics, which may limit transparency for investors. Warning! GuruFocus has detected 7 Warning Signs with CPK. Is AUPH fairly valued? Test your thesis with our free DCF calculator. Q: Your issued guidance for 2026 seems somewhat conservative given the 4Q run rate. What are some specifics informing the commercial outlook and what are you seeing in the first two months of this year? A: Our strategy for the commercial business of Luinis remains consistent, focusing on the efficacy of the product in treating lupus nephritis and reducing proteinuria. We leverage expanded data sets and guidelines to promote early and aggressive treatment. As for the first two months of the year, we are not providing specific guidance but suggest looking at Q1 of 2025 for trends. Q: You recently terminated the phase 3 and open-label studies in the vocal study and the vocal extension, the pediatric study. Can you clarify whether DSMB is asking to stop or is FDA refocused on the drug in any way? A: The decision to terminate the vocal study was due to technical issues with patient recruitment, not DSMB or FDA intervention. We plan to negotiate with the FDA to meet our pediatric commitments in lupus nephritis. Q: Can we expect a development update for eritinocept in early 2026, and could you provide context on the study design and size? A: We are excited about the potential of BA April inhibition in autoimmune diseases. We initiated a clinical study of eritinocept and plan another in early 2026. We will disclose indications in Q2 2026 but are not detailing trial design yet. Q: Could you talk about what's driving the continued strong performance of Luinis as we head into 2026? A: We are seeing growth across patients, solid adherence, and consistent performance in commercial metrics. Historical growth patterns are the best predictor for future performance, which is reflected in our guidance. Q: Do you expect other global markets to catch up to the US in terms of penetration in the lupus nephritis patient population? A: No, due to different pricing, reimbursement, and guidelines in each country. While international markets contribute to growth, they are not expected to match the aggressive treatment and pricing seen in the US. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

LUPKYNIS net product sales grew 25% year-over-year in 2025, driven by consistent patient adherence and stable commercial pricing dynamics. Management attributes commercial success to the adoption of ACR and EULAR guidelines, which advocate for aggressive proteinuria reduction and earlier diagnostic intervention. The company recorded a significant net income spike due to a $173 million income tax benefit for the full year from the release of valuation allowances on deferred tax assets. Strategic focus has shifted toward rheumatologists, who now represent a slightly larger share of the prescriber base than nephrologists due to their role in early-stage SLE diagnosis. Operational efficiency and revenue growth resulted in a 206% increase in annual cash flows from operating activities, reaching $135.7 million. The company executed a capital allocation strategy that reduced fully diluted shares outstanding from 149.8 million to 139.7 million through share repurchases. 2026 net product sales guidance of $305 million to $315 million assumes 12% to 16% growth, factoring in historical trends and new market competition. Management plans to disclose specific autoimmune indications for the aritinercept clinical program in the second quarter of 2026. A second clinical study for aritinercept is scheduled to initiate in the first half of 2026, targeting a separate B-cell mediated autoimmune disease. The company intends to negotiate with the FDA regarding pediatric commitments following the termination of the VOCAL pediatric study due to recruitment challenges. Future R&D exploration may include combining T-cell targeted LUPKYNIS with B-cell therapies to address breakthrough proteinuria in stable SLE patients. The Phase III VOCAL pediatric study was terminated due to technical recruitment difficulties; management noted the pediatric LN market is small with limited business impact. Phase I data for aritinercept showed low-titer anti-drug antibodies (ADAs) at doses above 25mg, though management reported no impact on safety or pharmacokinetics. International revenue from Otsuka partnerships in Europe and Japan is expected to remain a minor contributor due to lower pricing and varied reimbursement hurdles compared to the U.S. The release of a $173 million valuation allowance reflects management's confidence in the long-term profitability and realization of deferred tax assets. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management argues LUPKYNIS offers faster proteinuria reduction (50% within one month) compared to Gazyva’s 76-week primary endpoint. They believe the entry of new competitors will expand the total treated market by increasing diagnostic awareness and guideline adherence. Guidance is informed by historical growth patterns and the first two months of 2026, which management stated are consistent with past performance. The outlook incorporates the impact of new market entrants and the continued implementation of early-treatment medical guidelines. Management declined to specify current trial designs or indications to maintain competitive positioning until a full disclosure in Q2 2026. The program is being positioned as a 'beachhead' strategy to address multiple B-cell mediated inflammatory conditions. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.